Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.5382
+0.0482 (9.84%)
At close: Apr 2, 2025, 4:00 PM
0.5250
-0.0132 (-2.45%)
After-hours: Apr 2, 2025, 5:27 PM EST
Palatin Technologies Revenue
Palatin Technologies had revenue of $350.00K in the twelve months ending December 31, 2024, down -95.07% year-over-year. In the fiscal year ending June 30, 2024, Palatin Technologies had annual revenue of $4.49M, down -7.49%.
Revenue (ttm)
$350.00K
Revenue Growth
-95.07%
P/S Ratio
25.59
Revenue / Employee
$11,667
Employees
30
Market Cap
14.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
| Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
| Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
| Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
| Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PTN News
- 2 days ago - Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - PRNewsWire
- 5 days ago - Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - PRNewsWire
- 8 days ago - Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency - PRNewsWire
- 6 weeks ago - Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 - PRNewsWire
- 7 weeks ago - Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire
- 7 weeks ago - Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - PRNewsWire